Identification of new candidate drugs for lung cancer using chemical–chemical interactions, chemical–protein interactions and a K-means clustering algorithm

Lung cancer, characterized by uncontrolled cell growth in the lung tissue, is the leading cause of global cancer deaths. Until now, effective treatment of this disease is limited. Many synthetic compounds have emerged with the advancement of combinatorial chemistry. Identification of effective lung cancer candidate drug compounds among them is a great challenge. Thus, it is necessary to build effective computational methods that can assist us in selecting for potential lung cancer drug compounds. In this study, a computational method was proposed to tackle this problem. The chemical–chemical interactions and chemical–protein interactions were utilized to select candidate drug compounds that have close associations with approved lung cancer drugs and lung cancer-related genes. A permutation test and K-means clustering algorithm were employed to exclude candidate drugs with low possibilities to treat lung cancer. The final analysis suggests that the remaining drug compounds have potential anti-lung cancer activities and most of them have structural dissimilarity with approved drugs for lung cancer.

[1]  Lei Chen,et al.  Prediction of Cancer Drugs by Chemical-Chemical Interactions , 2014, PloS one.

[2]  S. Vijayakumar,et al.  Prediction of new cyanobacterial drug for treating lung cancer , 2014 .

[3]  Jing Lu,et al.  A hybrid method for prediction and repositioning of drug Anatomical Therapeutic Chemical classes. , 2014, Molecular bioSystems.

[4]  T. Owonikoko,et al.  Targeting Angiogenesis in Non-Small Cell Lung Cancer (NSCLC) , 2010 .

[5]  Xiaomin Luo,et al.  Estimation of acute oral toxicity in rat using local lazy learning , 2014, Journal of Cheminformatics.

[6]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..

[7]  Ettinger,et al.  Carboplatin in the Treatment of Small Cell Lung Cancer. , 1997, The oncologist.

[8]  P. Sunpaweravong,et al.  A Phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer , 2006, Investigational New Drugs.

[9]  M. Provencio,et al.  The role of anthracyclines in small cell lung cancer. , 2013, Annals of translational medicine.

[10]  Canguo Zhao,et al.  Expression-Based In Silico Screening of Candidate Therapeutic Compounds for Lung Adenocarcinoma , 2011, PloS one.

[11]  Xiao Li,et al.  In Silico Prediction of Chemical Acute Oral Toxicity Using Multi-Classification Methods , 2014, J. Chem. Inf. Model..

[12]  Kuo-Chen Chou,et al.  Predicting Biological Functions of Compounds Based on Chemical-Chemical Interactions , 2011, PloS one.

[13]  B. Curry,et al.  ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. , 2002, Cancer research.

[14]  J. MacQueen Some methods for classification and analysis of multivariate observations , 1967 .

[15]  S. Lam,et al.  The xc− cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine , 2009, Cancer Chemotherapy and Pharmacology.

[16]  S. Antonia,et al.  Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF. , 2011, Anticancer research.

[17]  G. Tortora,et al.  The role of EGFR inhibitors in nonsmall cell lung cancer , 2004, Current opinion in oncology.

[18]  Jon A Arnot,et al.  Estimating screening-level organic chemical half-lives in humans. , 2014, Environmental science & technology.

[19]  F. Ciardiello,et al.  Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Y. Miyagi,et al.  WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors , 2012, Laboratory Investigation.

[21]  S. Barry,et al.  Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer. , 2011, International journal of oncology.

[22]  T Sahmoud,et al.  Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy--a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  K. Havemann,et al.  Original article: Determining carboplatin/etoposide dosage in extensive stage small-cell lung cancer (SCLC) , 1991 .

[24]  Yan Sun,et al.  Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. , 2010, The Lancet. Oncology.

[25]  Lucio Crino,et al.  Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  E. Seifried,et al.  Prediction of the pathogenicity of antithrombin sequence variations by in silico methods. , 2015, Thrombosis research.

[27]  M. P. Goren,et al.  Oral mesna: a review. , 1992, Seminars in oncology.

[28]  Arlan da Silva Gonçalves,et al.  Reactivation steps by 2-PAM of tabun-inhibited human acetylcholinesterase: reducing the computational cost in hybrid QM/MM methods , 2014, Journal of biomolecular structure & dynamics.

[29]  M. Kalender,et al.  Irinotecan as a second-line monotherapy for small cell lung cancer. , 2011, Asian Pacific journal of cancer prevention : APJCP.

[30]  Vijay K. Gombar,et al.  Quantitative Structure − Activity Relationship Models of Clinical Pharmacokinetics : Clearance and Volume of Distribution , 2013 .

[31]  R. Herbst,et al.  Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  S. Dahrouge,et al.  A Phase II Study of 5‐Fluorouracil Plus High‐Dose Folinic Acid in the Treatment of Recurrent Small Cell Lung Cancer , 1995, American journal of clinical oncology.

[33]  H. Lynch,et al.  Psychologic Aspects of Cancer Genetic Testing: A Research Update for Clinicians , 1997 .

[34]  Yu-Dong Cai,et al.  Finding Candidate Drugs for Hepatitis C Based on Chemical-Chemical and Chemical-Protein Interactions , 2014, PloS one.

[35]  Ashalatha Sreshty Mamidi,et al.  Hierarchical sampling for metastable conformers determines biomolecular recognition: the case of malectin and diglucosylated N-glycan interactions , 2015, Journal of biomolecular structure & dynamics.

[36]  Jonna C. Stålring,et al.  Exploring in silico prediction of the unbound brain-to-plasma drug concentration ratio: model validation, renewal, and interpretation. , 2015, Journal of pharmaceutical sciences.

[37]  T. Ramalho,et al.  Employing conformational analysis in the molecular modeling of agrochemicals: insights on QSAR parameters of 2,4-D , 2013 .

[38]  M. Som Combined therapy. , 1972, JAMA.

[39]  Kwangsoo Kim,et al.  Mechanistic Insights into the Activation of Oncogenic Forms of EGF Receptor , 2011, Nature Structural &Molecular Biology.

[40]  T. Eisen,et al.  Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer , 2008, Thorax.

[41]  Kumardeep Chaudhary,et al.  In Silico Models for Designing and Discovering Novel Anticancer Peptides , 2013, Scientific Reports.

[42]  อนิรุธ สืบสิงห์,et al.  Data Mining Practical Machine Learning Tools and Techniques , 2014 .

[43]  J. Crowley,et al.  Teniposide (VM‐26) as a single drug treatment for patients with extensive small cell lung carcinoma , 1997, Cancer.

[44]  W Patrick Walters,et al.  What do medicinal chemists actually make? A 50-year retrospective. , 2011, Journal of medicinal chemistry.

[45]  Christian von Mering,et al.  STITCH: interaction networks of chemicals and proteins , 2007, Nucleic Acids Res..

[46]  Damian Szklarczyk,et al.  STITCH 4: integration of protein–chemical interactions with user data , 2013, Nucleic Acids Res..

[47]  K. Kiura,et al.  Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency. , 2013, Experimental cell research.

[48]  R. Jensen,et al.  Camptothecin-somatostatin conjugates inhibit the growth of small cell lung cancer cells , 2005, Peptides.

[49]  E. Shimizu,et al.  Sequential treatment with SN-38 followed by 5-fluorouracil shows synergistic cytotoxic activity in small cell lung cancer cells. , 2008, Oncology reports.

[50]  Matthew Meyerson,et al.  Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. , 2007, Cancer cell.

[51]  A. Rossi,et al.  Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  J. Crowley,et al.  Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trial. , 1999, The cancer journal from Scientific American.

[53]  Xiaofeng Liu,et al.  SHAFTS: A Hybrid Approach for 3D Molecular Similarity Calculation. 1. Method and Assessment of Virtual Screening , 2011, J. Chem. Inf. Model..

[54]  M. Fukuoka,et al.  Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer. , 2006, Anticancer research.

[55]  T. Mitsudomi,et al.  Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer , 2012, Molecular Cancer Therapeutics.

[56]  E. Smit,et al.  Single-agent gemcitabine in patients with resistant small-cell lung cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[57]  Alexander Tropsha,et al.  Quantitative structure-activity relationship modeling of rat acute toxicity by oral exposure. , 2009, Chemical research in toxicology.